Repurchase of Biogaran (generics): Gabriel Attal promises “exceptional vigilance”


The prospect of a possible sale of the Biogaran laboratory, which presents one box of medicines in eight sold in pharmacies and nearly a third of generic medicines in France, upsets the government (AFP/Archives/Christophe ARCHAMBAULT)

Prime Minister Gabriel Attal warned on Wednesday that “any non-European buyer” who would buy the French generic manufacturer Biogaran from the French laboratory Servier must expect “drastic conditions” and “exceptional vigilance”.

“We have been very clear with Servier: we do not want them to sell Biogaran,” declared the head of the executive during the question session to the government before the National Assembly.

“If, however, Servier still chose to sell Biogaran, yes, we would allow ourselves the possibility of activating the procedure for controlling foreign investments in France”, in order to “enforce our sovereignty”, he confirmed.

“We will be exceptionally vigilant and any non-European buyer, I say here publicly and clearly, must expect drastic conditions if they even want to hope to acquire Biogaran,” warned the Prime Minister. minister.

“Europe must be the vector of our sovereignty, particularly in terms of health and health products,” he repeated.

Before him, the Minister Delegate for Industry, Roland Lescure and the Minister Delegate for Health Frédéric Valletoux have already expressed their concern about a risk of relocation of production that the sale of Biogaran to a foreign actor.

The prospect of a possible sale of the laboratory which presents one box of medicines in eight sold in pharmacies and almost a third of generic medicines in France upsets the government, engaged in reconquering health sovereignty.

Two large Indian groups, Torrent Pharmaceuticals and Aurobindo Pharma, are cited as potential buyers of the number one generic company in France, as is the British investment company BC Partners.

The French pharmaceutical laboratory and subcontractor Benta Lyon is also in the running, according to an expert in the pharmaceutical sector.

However, the sale of Biogaran has not been officially confirmed and the potential buyers mentioned have refused to comment for weeks.

© 2024 AFP

Did you like this article ? Share it with your friends using the buttons below.


Twitter


Facebook


Linkedin


E-mail





Source link -85